InspireMD (NSPR) Q1 2026 earnings review
Record Revenue Overshadowed by Critical U.S. Product Recall
InspireMD posted its highest quarterly revenue to date at $3.4M (accelerating to 122% YoY growth), driven by a 36% sequential surge in U.S. sales. However, this commercial momentum has hit a sudden wall: the company initiated a voluntary U.S. recall of its flagship CGuard Prime 135 cm delivery system to address performance issues. This severely derails the near-term investment thesis. The recall immediately compressed gross margins from 37.5% in 25Q4 to 20.2% in 26Q1 due to inventory impairment charges. With a net loss widening to $13.7M, the commercial pause threatens the company's cash runway and its ability to trigger future milestone-based financing tranches.
🐂 Bull Case
Prior to the recall, U.S. market adoption was accelerating, contributing $1.2M in 26Q1 revenue (up 36% QoQ) and completing over 625 cumulative procedures since launch.
The company's long-term value driver—the TCAR indication—remains on track. FDA IDE approval was secured for the CGUARDIANS III trial evaluating the SwitchGuard neuroprotection system.
🐻 Bear Case
The voluntary recall of the CGuard Prime 135 cm system abruptly halts the company's primary growth engine until enhancements are implemented, introducing significant execution risk.
Operating expenses jumped to $14.7M as the company staffs a U.S. commercial team that now has a compromised product offering, accelerating cash burn.
⚖️ Verdict: 🔴
Bearish. While underlying demand is evident, the U.S. recall is a catastrophic short-term blow. It directly contradicts management's Q4 narrative of 'proactive' enhancements, revealing a serious technical flaw that breaks the commercial momentum required to sustain their heavy operating expenses.
Key Themes
The 'Proactive Enhancement' Was Actually a Recall
During the 25Q4 earnings call, management framed the introduction of an enhanced delivery system as a proactive step to improve 'ease of use.' The 26Q1 release reveals the stark reality: a voluntary U.S. recall of the CGuard Prime 135 cm system to address 'technical performance' issues. This contradiction damages management credibility and highlights significant friction in the initial product rollout.
U.S. Revenue Was Accelerating Pre-Recall
Despite the recall crisis, the underlying data shows the product was gaining serious traction. U.S. revenue grew sequentially from $0.5M in 25Q3, to $0.9M in 25Q4, to $1.2M in 26Q1. The company has penetrated over 100 leading U.S. hospitals. If the delivery system fix is rapid, the demand funnel appears robust.
Margin Reversal and Recall Costs
The mix-shift to the U.S. was expected to drive margins toward 70%. Instead, the recall caused a sudden reversal. GAAP gross margin plummeted to 20.2% in 26Q1 (down from 37.5% in 25Q4), heavily impacted by a $0.5M inventory impairment charge. The company expects an additional $0.7M reserve for customer returns and another $0.65M for further inventory impairment and remediation.
TCAR Pipeline Progresses Unimpeded
Management explicitly stated the Transcarotid Artery Revascularization (TCAR) program is unaffected by the CAS delivery system recall. The company secured FDA IDE approval to initiate the CGUARDIANS III trial for the SwitchGuard neuroprotection system. They remain on track for H2 2026 approval of the CGuard Prime 80 cm for TCAR, preserving the long-term thesis of accessing a 35,000+ annual procedure market.
Regulatory Fallback Strategy
To mitigate the U.S. commercial pause, InspireMD is pursuing FDA approval of the original, older-generation CGuard stent delivery system, expected in Q3 2026. Having been used in over 70,000 implants globally, this acts as a proven stopgap to offer U.S. physicians while the Prime 135 cm system is being re-engineered.
Cash Burn and Financing Triggers
Operating expenses accelerated to $14.7M (up from $11.8M YoY) primarily due to U.S. commercial headcount. The company holds ~$41.6M in liquid assets (cash + marketable securities). A major risk is that remaining milestone-based financing tranches ($17.9M each) require four quarters of U.S. commercial sales—the current recall threatens to disrupt this continuity and pressure the balance sheet.
International Market Stability
While the U.S. is the primary growth engine, international operations remain a stable foundation. Q1 2026 international revenue reached $2.2M, representing stable 48% YoY growth, providing modest but vital cash flow to offset U.S. disruptions.
Other KPIs
Excluding the $0.5M inventory impairment charge associated with the recall, adjusted gross margin was 34.1%. This reflects the underlying profitability of the business and the favorable U.S. sales mix, though it still falls short of typical 70%+ medical device margins until volume scales.
Consists of $11.36M in cash and equivalents plus $30.2M in marketable securities. This represents a sequential decrease from $54.2M at the end of 25Q4, reflecting the heavy cash burn required to sustain the U.S. commercial footprint.
Guidance
The company expects FDA approval of its legacy delivery system in the third quarter. This is a critical near-term target to restore a U.S. product offering while the next-generation CGuard Prime 135 cm undergoes technical enhancements.
Stable. The company remains on track for expected FDA approval of the shorter 80 cm stent for TCAR procedures in the second half of 2026, which they claim will potentially double their addressable market.
Management expects future financial impacts from the U.S. recall to include a $700,000 reserve for customer returns and roughly $650,000 for additional inventory impairment and remediation costs. This will severely weigh on Q2 margins.
Key Questions
Timeline for CGuard Prime Return
How long will the CGuard Prime 135 cm system be off the U.S. market? Are the required 'technical enhancements' a matter of manufacturing tweaks, or do they require a new round of FDA clearance and review?
Milestone Financing Triggers
The May 2023 private placement included a $17.9M tranche contingent on achieving four full quarters of U.S. commercial sales. Does the voluntary recall and subsequent pause in U.S. sales reset the clock on this critical milestone?
Sales Force Retention and Productivity
With the primary U.S. product pulled from shelves, what is the strategy for maintaining the productivity and morale of the 30+ person commercial team? Will operating expenses be rationalized during the commercial pause?
Spillover Risk to TCAR
While management states the TCAR program is unaffected, does the technical failure of the CGuard Prime 135 cm delivery system share any components or design architecture with the CGuard Prime 80 cm system currently under FDA review for TCAR?